Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. LEGN
LEGN logo

LEGN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Legend Biotech Corp (LEGN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
20.270
1 Day change
3.63%
52 Week Range
45.300
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Legend Biotech Corp (LEGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, declining financial performance, and mixed analyst sentiment. While the company's revenue growth is notable, its net income and EPS are significantly down, and competition concerns are weighing heavily on its future outlook. Given the lack of strong positive catalysts and no Intellectia Proprietary Trading Signals, it is better to hold off on investing in this stock for now.

Technical Analysis

The technical indicators for LEGN are bearish. The MACD is positive but contracting, RSI is neutral at 31.825, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 17.682, with resistance at 20.83. This suggests limited upward momentum in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

The high put-call volume ratio indicates bearish sentiment among options traders, with a significant skew towards put options.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
9

Positive Catalysts

  • Revenue growth of 69.99% YoY in Q3 2025 demonstrates strong top-line performance. Analysts like Oppenheimer see the stock as undervalued and believe the risk/reward is skewed to the upside.

Neutral/Negative Catalysts

  • Declining net income (-68.33% YoY) and EPS (-67.65% YoY) indicate worsening profitability. Analyst downgrades, including a significant price target cut by Rothschild & Co Redburn, highlight concerns about competition and demand for the company's flagship product, Carvykti. The bearish sentiment in options trading further adds to the negative outlook.

Financial Performance

In Q3 2025, revenue increased by 69.99% YoY to $272.33M. However, net income dropped by 68.33% YoY to -$39.69M, and EPS fell by 67.65% YoY to -0.11. Gross margin also declined to 57.66%, down 11.81% YoY, indicating profitability challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed but leaning negative. Recent downgrades from Rothschild & Co Redburn and TD Cowen highlight concerns over competition and demand for Carvykti. However, some analysts like Oppenheimer and Cantor Fitzgerald remain optimistic, citing undervaluation and differentiation of Carvykti. Price targets have been significantly lowered across the board, reflecting cautious sentiment.

Wall Street analysts forecast LEGN stock price to rise
11 Analyst Rating
Wall Street analysts forecast LEGN stock price to rise
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 19.560
sliders
Low
48
Averages
68.1
High
90
Current: 19.560
sliders
Low
48
Averages
68.1
High
90
Deutsche Bank
maintain
$3.5B
AI Analysis
2026-03-09
New
Reason
Deutsche Bank
Price Target
$3.5B
AI Analysis
2026-03-09
New
maintain
Reason
Deutsche Bank attributes the 46% selloff in Legend Biotech shares over the past 12 months to market share concerns are "overblown and dislocated from fundamentals." The firm is aware of the perceived clinical differentiation between the various BCMA CAR-Ts and bispecifics, but believes the combination of multiple myeloma's large patient population and "intense" CAR-T manufacturing requirements supports multiple players. Deutsche estimates peak gross Carvykti sales at $7B with Legend's pro-rata share at $3.5B. It sees a favorable risk/reward at current share levels.
Rothschild & Co Redburn
Qize Ding
Buy -> Neutral
downgrade
$83 -> $24
2026-02-12
Reason
Rothschild & Co Redburn
Qize Ding
Price Target
$83 -> $24
2026-02-12
downgrade
Buy -> Neutral
Reason
Rothschild & Co Redburn analyst Qize Ding downgraded Legend Biotech to Neutral from Buy with a price target of $24, down from $83. The firm believes Legend Biotech's only marketed product, Carvykti, will face major competition across all line settings of multiple myeloma following the ASH 2025 conference, the analyst tells investors. The firm's survey work suggests "a strong willingness" from physicians for adoption of bispecific-based therapy in the earlier line settings in the short term, the analyst added. The firm lowered its global peak sales estimates to $6B from $10B, placing its forecast about 16% below consensus, the analyst noted.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LEGN
Unlock Now

People Also Watch